BR112020008850A2 - composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 - Google Patents

Info

Publication number

BR112020008850A2

BR112020008850A2 BR112020008850-1A BR112020008850A BR112020008850A2 BR 112020008850 A2 BR112020008850 A2 BR 112020008850A2 BR 112020008850 A BR112020008850 A BR 112020008850A BR 112020008850 A2 BR112020008850 A2 BR 112020008850A2

Authority

BR

Brazil

Prior art keywords

methyl

amino

pyrrole

carboxylate

pyridine

Prior art date

2017-11-03

Links

• Espacenet
• Global Dossier
• Discuss

• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 88
• 201000010099 disease Diseases 0.000 title claims abstract description 53
• 238000000034 method Methods 0.000 title claims abstract description 46
• 150000001875 compounds Chemical class 0.000 title claims description 174
• 230000001404 mediated effect Effects 0.000 title claims description 23
• 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
• 101150079478 jak1 gene Proteins 0.000 title 1
• 206010047642 Vitiligo Diseases 0.000 claims abstract description 79
• 201000004384 Alopecia Diseases 0.000 claims abstract description 49
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims abstract description 39
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims abstract description 39
• 231100000360 alopecia Toxicity 0.000 claims abstract description 36
• 239000003814 drug Substances 0.000 claims abstract description 31
• 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims abstract description 17
• 201000004681 Psoriasis Diseases 0.000 claims abstract description 17
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims abstract description 17
• 208000003251 Pruritus Diseases 0.000 claims abstract 93
• 230000007803 itching Effects 0.000 claims abstract 34
• 201000002996 androgenic alopecia Diseases 0.000 claims abstract 9
• 206010068168 androgenetic alopecia Diseases 0.000 claims abstract 5
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 442
• 125000000217 alkyl group Chemical group 0.000 claims description 382
• -1 4- (cyclopentyl-amino) -1H-pyrrole Chemical compound 0.000 claims description 327
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 326
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 262
• 229910052736 halogen Inorganic materials 0.000 claims description 126
• 150000002367 halogens Chemical class 0.000 claims description 124
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 86
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 86
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 82
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 80
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 66
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 66
• 230000001363 autoimmune Effects 0.000 claims description 59
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 58
• 150000003839 salts Chemical class 0.000 claims description 56
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 46
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 46
• 125000003118 aryl group Chemical group 0.000 claims description 41
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 41
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 40
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 40
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 37
• 125000005842 heteroatom Chemical group 0.000 claims description 36
• 208000035475 disorder Diseases 0.000 claims description 35
• 125000004432 carbon atom Chemical group C* 0.000 claims description 34
• 125000001072 heteroaryl group Chemical group 0.000 claims description 34
• 125000000623 heterocyclic group Chemical group 0.000 claims description 34
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 32
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 31
• 125000001424 substituent group Chemical group 0.000 claims description 30
• 150000007942 carboxylates Chemical class 0.000 claims description 28
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 28
• 125000003545 alkoxy group Chemical group 0.000 claims description 26
• 229910052799 carbon Inorganic materials 0.000 claims description 24
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 24
• 239000003795 chemical substances by application Substances 0.000 claims description 24
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 23
• 239000012453 solvate Substances 0.000 claims description 23
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 20
• 201000008937 atopic dermatitis Diseases 0.000 claims description 20
• 238000006243 chemical reaction Methods 0.000 claims description 19
• 125000005843 halogen group Chemical group 0.000 claims description 19
• 239000002253 acid Substances 0.000 claims description 18
• 229940079593 drug Drugs 0.000 claims description 17
• RDBBFJAPMNVENH-UHFFFAOYSA-N methyl 1h-pyrazolo[4,3-b]pyridine-5-carboxylate Chemical compound COC(=O)C1=CC=C2NN=CC2=N1 RDBBFJAPMNVENH-UHFFFAOYSA-N 0.000 claims description 17
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 16
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 15
• 125000002619 bicyclic group Chemical group 0.000 claims description 15
• 125000004122 cyclic group Chemical group 0.000 claims description 15
• 230000009885 systemic effect Effects 0.000 claims description 15
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 14
• YSIKHBWUBSFBRZ-UHFFFAOYSA-N 3-methoxypropanoic acid Chemical compound COCCC(O)=O YSIKHBWUBSFBRZ-UHFFFAOYSA-N 0.000 claims description 14
• 101150065749 Churc1 gene Proteins 0.000 claims description 14
• XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 claims description 14
• 102100038239 Protein Churchill Human genes 0.000 claims description 14
• 206010061218 Inflammation Diseases 0.000 claims description 13
• 230000004054 inflammatory process Effects 0.000 claims description 13
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
• 229910052717 sulfur Inorganic materials 0.000 claims description 13
• 229910052739 hydrogen Inorganic materials 0.000 claims description 12
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
• 239000008186 active pharmaceutical agent Substances 0.000 claims description 11
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 11
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
• 229940124597 therapeutic agent Drugs 0.000 claims description 11
• 229910052757 nitrogen Inorganic materials 0.000 claims description 10
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
• 206010052779 Transplant rejections Diseases 0.000 claims description 9
• 208000023275 Autoimmune disease Diseases 0.000 claims description 8
• 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 8
• UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims description 7
• 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 7
• 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 7
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 6
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
• 150000001345 alkine derivatives Chemical class 0.000 claims description 6
• 208000026935 allergic disease Diseases 0.000 claims description 6
• 210000004027 cell Anatomy 0.000 claims description 6
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
• 206010013774 Dry eye Diseases 0.000 claims description 5
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
• 229910052731 fluorine Inorganic materials 0.000 claims description 5
• 230000002489 hematologic effect Effects 0.000 claims description 5
• 239000007943 implant Substances 0.000 claims description 5
• 208000027866 inflammatory disease Diseases 0.000 claims description 5
• 230000007794 irritation Effects 0.000 claims description 5
• 229910052751 metal Inorganic materials 0.000 claims description 5
• 239000002184 metal Substances 0.000 claims description 5
• 229920001296 polysiloxane Polymers 0.000 claims description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
• DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims description 4
• NLZUHYGTGTWCML-UHFFFAOYSA-N 2-methoxyethyl pyridine-3-carboxylate Chemical compound COCCOC(=O)C1=CC=CN=C1 NLZUHYGTGTWCML-UHFFFAOYSA-N 0.000 claims description 4
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
• OZYHLCOUAISLLG-UHFFFAOYSA-N cyclopropyl acetate Chemical compound CC(=O)OC1CC1 OZYHLCOUAISLLG-UHFFFAOYSA-N 0.000 claims description 4
• NVSNEXNZCAUDOI-UHFFFAOYSA-N cyclopropylmethyl pyridine-3-carboxylate Chemical compound C=1C=CN=CC=1C(=O)OCC1CC1 NVSNEXNZCAUDOI-UHFFFAOYSA-N 0.000 claims description 4
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 3
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
• OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 claims description 3
• 239000011737 fluorine Substances 0.000 claims description 3
• 208000015181 infectious disease Diseases 0.000 claims description 3
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
• VPUAYOJTHRDUTK-UHFFFAOYSA-N 1-ethylpyrrole Chemical compound CCN1C=CC=C1 VPUAYOJTHRDUTK-UHFFFAOYSA-N 0.000 claims description 2
• MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 claims description 2
• FWYJHLZHLDGOSG-UHFFFAOYSA-N C(CCC1)CCC1NC1=CNC=C1 Chemical compound C(CCC1)CCC1NC1=CNC=C1 FWYJHLZHLDGOSG-UHFFFAOYSA-N 0.000 claims description 2
• 208000004631 alopecia areata Diseases 0.000 claims description 2
• 235000008429 bread Nutrition 0.000 claims description 2
• 206010028980 Neoplasm Diseases 0.000 claims 55
• 208000011580 syndromic disease Diseases 0.000 claims 39
• 230000003448 neutrophilic effect Effects 0.000 claims 34
• 206010016654 Fibrosis Diseases 0.000 claims 31
• 201000011510 cancer Diseases 0.000 claims 28
• 206010025135 lupus erythematosus Diseases 0.000 claims 28
• 230000001684 chronic effect Effects 0.000 claims 27
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 25
• 230000002757 inflammatory effect Effects 0.000 claims 25
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 25
• 208000002874 Acne Vulgaris Diseases 0.000 claims 24
• 206010000496 acne Diseases 0.000 claims 24
• 206010003246 arthritis Diseases 0.000 claims 23
• 230000004761 fibrosis Effects 0.000 claims 23
• 208000024780 Urticaria Diseases 0.000 claims 22
• 206010025323 Lymphomas Diseases 0.000 claims 20
• 230000037390 scarring Effects 0.000 claims 20
• 206010047115 Vasculitis Diseases 0.000 claims 19
• 230000001154 acute effect Effects 0.000 claims 19
• 208000017169 kidney disease Diseases 0.000 claims 19
• 208000003456 Juvenile Arthritis Diseases 0.000 claims 17
• 230000005722 itchiness Effects 0.000 claims 17
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims 16
• 206010040070 Septic Shock Diseases 0.000 claims 16
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 16
• 208000019425 cirrhosis of liver Diseases 0.000 claims 16
• 208000033679 diabetic kidney disease Diseases 0.000 claims 16
• 208000017520 skin disease Diseases 0.000 claims 16
• 206010020751 Hypersensitivity Diseases 0.000 claims 14
• 230000036210 malignancy Effects 0.000 claims 14
• 208000002193 Pain Diseases 0.000 claims 13
• 206010039710 Scleroderma Diseases 0.000 claims 13
• 208000032839 leukemia Diseases 0.000 claims 13
• 231100000241 scar Toxicity 0.000 claims 13
• 206010003645 Atopy Diseases 0.000 claims 12
• 201000004624 Dermatitis Diseases 0.000 claims 12
• 206010048768 Dermatosis Diseases 0.000 claims 12
• 208000017604 Hodgkin disease Diseases 0.000 claims 12
• 206010040047 Sepsis Diseases 0.000 claims 12
• 230000003676 hair loss Effects 0.000 claims 12
• 206010028537 myelofibrosis Diseases 0.000 claims 12
• 230000009826 neoplastic cell growth Effects 0.000 claims 12
• 206010058105 Neutrophilic dermatosis Diseases 0.000 claims 11
• 208000010668 atopic eczema Diseases 0.000 claims 11
• 230000002496 gastric effect Effects 0.000 claims 11
• 208000003476 primary myelofibrosis Diseases 0.000 claims 10
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 10
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims 9
• 210000003734 kidney Anatomy 0.000 claims 9
• 210000004185 liver Anatomy 0.000 claims 9
• 230000035935 pregnancy Effects 0.000 claims 9
• 210000003491 skin Anatomy 0.000 claims 9
• 208000004300 Atrophic Gastritis Diseases 0.000 claims 8
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 8
• 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 8
• 208000024172 Cardiovascular disease Diseases 0.000 claims 8
• 206010012442 Dermatitis contact Diseases 0.000 claims 8
• 208000036495 Gastritis atrophic Diseases 0.000 claims 8
• 208000024869 Goodpasture syndrome Diseases 0.000 claims 8
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 8
• 201000009495 Hypotrichosis Diseases 0.000 claims 8
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 8
• 208000002260 Keloid Diseases 0.000 claims 8
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 8
• 208000034578 Multiple myelomas Diseases 0.000 claims 8
• 206010028424 Myasthenic syndrome Diseases 0.000 claims 8
• 208000009525 Myocarditis Diseases 0.000 claims 8
• 201000002481 Myositis Diseases 0.000 claims 8
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 8
• 206010034277 Pemphigoid Diseases 0.000 claims 8
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 8
• 206010035664 Pneumonia Diseases 0.000 claims 8
• 208000017442 Retinal disease Diseases 0.000 claims 8
• 206010038923 Retinopathy Diseases 0.000 claims 8
• 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 8
• 206010039705 Scleritis Diseases 0.000 claims 8
• 201000008736 Systemic mastocytosis Diseases 0.000 claims 8
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 8
• 208000024799 Thyroid disease Diseases 0.000 claims 8
• 206010044248 Toxic shock syndrome Diseases 0.000 claims 8
• 231100000650 Toxic shock syndrome Toxicity 0.000 claims 8
• 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims 8
• 230000001476 alcoholic effect Effects 0.000 claims 8
• 208000006673 asthma Diseases 0.000 claims 8
• 230000005784 autoimmunity Effects 0.000 claims 8
• 208000016644 chronic atrophic gastritis Diseases 0.000 claims 8
• 208000019069 chronic childhood arthritis Diseases 0.000 claims 8
• 230000007882 cirrhosis Effects 0.000 claims 8
• 210000001072 colon Anatomy 0.000 claims 8
• 208000010247 contact dermatitis Diseases 0.000 claims 8
• 201000001981 dermatomyositis Diseases 0.000 claims 8
• 206010012601 diabetes mellitus Diseases 0.000 claims 8
• 230000003176 fibrotic effect Effects 0.000 claims 8
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims 8
• 210000001117 keloid Anatomy 0.000 claims 8
• 206010023332 keratitis Diseases 0.000 claims 8
• 208000028454 lice infestation Diseases 0.000 claims 8
• 210000004072 lung Anatomy 0.000 claims 8
• 206010028417 myasthenia gravis Diseases 0.000 claims 8
• 201000005962 mycosis fungoides Diseases 0.000 claims 8
• 208000033808 peripheral neuropathy Diseases 0.000 claims 8
• 210000003800 pharynx Anatomy 0.000 claims 8
• 208000005069 pulmonary fibrosis Diseases 0.000 claims 8
• 201000002793 renal fibrosis Diseases 0.000 claims 8
• 230000036303 septic shock Effects 0.000 claims 8
• 201000005671 spondyloarthropathy Diseases 0.000 claims 8
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims 8
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 7
• 201000006082 Chickenpox Diseases 0.000 claims 7
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 7
• 208000012654 Primary biliary cholangitis Diseases 0.000 claims 7
• 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 7
• 206010046980 Varicella Diseases 0.000 claims 7
• 208000007502 anemia Diseases 0.000 claims 7
• 230000000750 progressive effect Effects 0.000 claims 7
• 230000001823 pruritic effect Effects 0.000 claims 7
• 208000037803 restenosis Diseases 0.000 claims 7
• 210000000988 bone and bone Anatomy 0.000 claims 6
• YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 6
• 208000002574 reactive arthritis Diseases 0.000 claims 6
• 208000003014 Bites and Stings Diseases 0.000 claims 5
• 206010073960 CANDLE syndrome Diseases 0.000 claims 5
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
• 206010015150 Erythema Diseases 0.000 claims 5
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 5
• 241000238631 Hexapoda Species 0.000 claims 5
• 208000011623 Obstructive Lung disease Diseases 0.000 claims 5
• 201000002661 Spondylitis Diseases 0.000 claims 5
• 206010043255 Tendonitis Diseases 0.000 claims 5
• 230000007815 allergy Effects 0.000 claims 5
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 5
• 210000004351 coronary vessel Anatomy 0.000 claims 5
• 208000020947 enthesitis Diseases 0.000 claims 5
• 231100000321 erythema Toxicity 0.000 claims 5
• 230000035876 healing Effects 0.000 claims 5
• 230000002949 hemolytic effect Effects 0.000 claims 5
• 230000002981 neuropathic effect Effects 0.000 claims 5
• 208000017502 proteosome-associated autoinflammatory syndrome Diseases 0.000 claims 5
• 230000001185 psoriatic effect Effects 0.000 claims 5
• OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims 4
• 208000007122 AIDS-Associated Nephropathy Diseases 0.000 claims 4
• 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 4
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 4
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
• 208000026872 Addison Disease Diseases 0.000 claims 4
• 206010002198 Anaphylactic reaction Diseases 0.000 claims 4
• 206010003571 Astrocytoma Diseases 0.000 claims 4
• 208000022715 Autoinflammatory syndrome Diseases 0.000 claims 4
• 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 4
• 208000037157 Azotemia Diseases 0.000 claims 4
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
• 208000003950 B-cell lymphoma Diseases 0.000 claims 4
• 208000035143 Bacterial infection Diseases 0.000 claims 4
• 206010004664 Biliary fibrosis Diseases 0.000 claims 4
• 208000013165 Bowen disease Diseases 0.000 claims 4
• 208000019337 Bowen disease of the skin Diseases 0.000 claims 4
• 206010006448 Bronchiolitis Diseases 0.000 claims 4
• 206010062746 Carditis Diseases 0.000 claims 4
• 208000005024 Castleman disease Diseases 0.000 claims 4
• 206010008609 Cholangitis sclerosing Diseases 0.000 claims 4
• 206010008635 Cholestasis Diseases 0.000 claims 4
• 208000002691 Choroiditis Diseases 0.000 claims 4
• 208000000094 Chronic Pain Diseases 0.000 claims 4
• 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 claims 4
• 208000032544 Cicatrix Diseases 0.000 claims 4
• 208000015943 Coeliac disease Diseases 0.000 claims 4
• 208000011231 Crohn disease Diseases 0.000 claims 4
• 201000003883 Cystic fibrosis Diseases 0.000 claims 4
• 208000001840 Dandruff Diseases 0.000 claims 4
• 206010011878 Deafness Diseases 0.000 claims 4
• 208000002162 Delusional Parasitosis Diseases 0.000 claims 4
• 206010012434 Dermatitis allergic Diseases 0.000 claims 4
• 206010051651 Dermatitis papillaris capillitii Diseases 0.000 claims 4
• 208000003024 Diffuse alopecia Diseases 0.000 claims 4
• 206010013786 Dry skin Diseases 0.000 claims 4
• 208000004232 Enteritis Diseases 0.000 claims 4
• 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 4
• 206010015084 Episcleritis Diseases 0.000 claims 4
• 208000032027 Essential Thrombocythemia Diseases 0.000 claims 4
• 208000010201 Exanthema Diseases 0.000 claims 4
• 206010015943 Eye inflammation Diseases 0.000 claims 4
• 206010016207 Familial Mediterranean fever Diseases 0.000 claims 4
• 208000007659 Fibroadenoma Diseases 0.000 claims 4
• 208000001640 Fibromyalgia Diseases 0.000 claims 4
• 201000008808 Fibrosarcoma Diseases 0.000 claims 4
• 206010016935 Follicular thyroid cancer Diseases 0.000 claims 4
• 206010016936 Folliculitis Diseases 0.000 claims 4
• 206010017533 Fungal infection Diseases 0.000 claims 4
• 206010058872 Fungal sepsis Diseases 0.000 claims 4
• 208000007882 Gastritis Diseases 0.000 claims 4
• 208000018522 Gastrointestinal disease Diseases 0.000 claims 4
• 208000007465 Giant cell arteritis Diseases 0.000 claims 4
• 208000032612 Glial tumor Diseases 0.000 claims 4
• 201000010915 Glioblastoma multiforme Diseases 0.000 claims 4
• 206010018338 Glioma Diseases 0.000 claims 4
• 206010018364 Glomerulonephritis Diseases 0.000 claims 4
• 206010051920 Glomerulonephropathy Diseases 0.000 claims 4
• 208000002705 Glucose Intolerance Diseases 0.000 claims 4
• 206010018429 Glucose tolerance impaired Diseases 0.000 claims 4
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 4
• 208000003807 Graves Disease Diseases 0.000 claims 4
• 208000015023 Graves' disease Diseases 0.000 claims 4
• 206010070737 HIV associated nephropathy Diseases 0.000 claims 4
• 208000004547 Hallucinations Diseases 0.000 claims 4
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 4
• 206010019668 Hepatic fibrosis Diseases 0.000 claims 4
• 208000005176 Hepatitis C Diseases 0.000 claims 4
• 206010019728 Hepatitis alcoholic Diseases 0.000 claims 4
• 208000023105 Huntington disease Diseases 0.000 claims 4
• 206010058490 Hyperoxia Diseases 0.000 claims 4
• 201000002980 Hyperparathyroidism Diseases 0.000 claims 4
• 206010020772 Hypertension Diseases 0.000 claims 4
• 206010062767 Hypophysitis Diseases 0.000 claims 4
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 4
• 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 4
• 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 4
• 208000029462 Immunodeficiency disease Diseases 0.000 claims 4
• 206010061217 Infestation Diseases 0.000 claims 4
• 208000005615 Interstitial Cystitis Diseases 0.000 claims 4
• 208000029523 Interstitial Lung disease Diseases 0.000 claims 4
• 206010023126 Jaundice Diseases 0.000 claims 4
• 208000012528 Juvenile dermatomyositis Diseases 0.000 claims 4
• 208000007766 Kaposi sarcoma Diseases 0.000 claims 4
• 206010023330 Keloid scar Diseases 0.000 claims 4
• 208000012309 Linear IgA disease Diseases 0.000 claims 4
• 208000004852 Lung Injury Diseases 0.000 claims 4
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
• 208000002805 Mediastinal fibrosis Diseases 0.000 claims 4
• 208000027530 Meniere disease Diseases 0.000 claims 4
• 201000009906 Meningitis Diseases 0.000 claims 4
• 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
• 208000014767 Myeloproliferative disease Diseases 0.000 claims 4
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 4
• 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims 4
• 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims 4
• 108010025020 Nerve Growth Factor Proteins 0.000 claims 4
• 102000007072 Nerve Growth Factors Human genes 0.000 claims 4
• 208000012902 Nervous system disease Diseases 0.000 claims 4
• 206010029216 Nervousness Diseases 0.000 claims 4
• 206010029260 Neuroblastoma Diseases 0.000 claims 4
• 201000009053 Neurodermatitis Diseases 0.000 claims 4
• 208000025966 Neurological disease Diseases 0.000 claims 4
• 208000008589 Obesity Diseases 0.000 claims 4
• 206010029888 Obliterative bronchiolitis Diseases 0.000 claims 4
• 206010030216 Oesophagitis Diseases 0.000 claims 4
• 208000003435 Optic Neuritis Diseases 0.000 claims 4
• 206010033165 Ovarian failure Diseases 0.000 claims 4
• 206010033733 Papule Diseases 0.000 claims 4
• 208000030852 Parasitic disease Diseases 0.000 claims 4
• 208000018737 Parkinson disease Diseases 0.000 claims 4
• 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 4
• 208000031845 Pernicious anaemia Diseases 0.000 claims 4
• 208000037581 Persistent Infection Diseases 0.000 claims 4
• 241001674048 Phthiraptera Species 0.000 claims 4
• 206010065159 Polychondritis Diseases 0.000 claims 4
• 208000003971 Posterior uveitis Diseases 0.000 claims 4
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims 4
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims 4
• 241000517305 Pthiridae Species 0.000 claims 4
• 201000003699 Punctate palmoplantar keratoderma Diseases 0.000 claims 4
• 206010037549 Purpura Diseases 0.000 claims 4
• 241001672981 Purpura Species 0.000 claims 4
• 208000006311 Pyoderma Diseases 0.000 claims 4
• 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 4
• 206010063837 Reperfusion injury Diseases 0.000 claims 4
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
• 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 4
• 201000001949 Retinal Vasculitis Diseases 0.000 claims 4
• 206010039509 Scab Diseases 0.000 claims 4
• 206010039580 Scar Diseases 0.000 claims 4
• 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 4
• 201000010208 Seminoma Diseases 0.000 claims 4
• 206010040880 Skin irritation Diseases 0.000 claims 4
• 206010070835 Skin sensitisation Diseases 0.000 claims 4
• 206010041067 Small cell lung cancer Diseases 0.000 claims 4
• 208000006045 Spondylarthropathies Diseases 0.000 claims 4
• 206010041955 Stasis dermatitis Diseases 0.000 claims 4
• 208000007107 Stomach Ulcer Diseases 0.000 claims 4
• 206010042496 Sunburn Diseases 0.000 claims 4
• 208000010265 Sweet syndrome Diseases 0.000 claims 4
• 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 4
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 4
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 4
• 208000001106 Takayasu Arteritis Diseases 0.000 claims 4
• 206010043276 Teratoma Diseases 0.000 claims 4
• 206010043866 Tinea capitis Diseases 0.000 claims 4
• 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
• 206010069363 Traumatic lung injury Diseases 0.000 claims 4
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 4
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 4
• 206010046798 Uterine leiomyoma Diseases 0.000 claims 4
• 206010046851 Uveitis Diseases 0.000 claims 4
• 208000036142 Viral infection Diseases 0.000 claims 4
• 208000008526 Wells syndrome Diseases 0.000 claims 4
• 206010052428 Wound Diseases 0.000 claims 4
• 208000027418 Wounds and injury Diseases 0.000 claims 4
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
• 208000017733 acquired polycythemia vera Diseases 0.000 claims 4
• 230000013564 activation of immune response Effects 0.000 claims 4
• 206010069351 acute lung injury Diseases 0.000 claims 4
• 208000005298 acute pain Diseases 0.000 claims 4
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
• 206010064930 age-related macular degeneration Diseases 0.000 claims 4
• 208000002353 alcoholic hepatitis Diseases 0.000 claims 4
• 230000036783 anaphylactic response Effects 0.000 claims 4
• 208000003455 anaphylaxis Diseases 0.000 claims 4
• 230000033115 angiogenesis Effects 0.000 claims 4
• 239000002260 anti-inflammatory agent Substances 0.000 claims 4
• 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
• 230000001028 anti-proliverative effect Effects 0.000 claims 4
• 239000002246 antineoplastic agent Substances 0.000 claims 4
• 230000003143 atherosclerotic effect Effects 0.000 claims 4
• 208000010216 atopic IgE responsiveness Diseases 0.000 claims 4
• 230000001746 atrial effect Effects 0.000 claims 4
• 230000006472 autoimmune response Effects 0.000 claims 4
• 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 4
• 208000022362 bacterial infectious disease Diseases 0.000 claims 4
• 210000004556 brain Anatomy 0.000 claims 4
• 210000000481 breast Anatomy 0.000 claims 4
• 201000003848 bronchiolitis obliterans Diseases 0.000 claims 4
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 4
• 206010006451 bronchitis Diseases 0.000 claims 4
• 208000000594 bullous pemphigoid Diseases 0.000 claims 4
• 230000000747 cardiac effect Effects 0.000 claims 4
• 230000009787 cardiac fibrosis Effects 0.000 claims 4
• 210000003169 central nervous system Anatomy 0.000 claims 4
• 208000026106 cerebrovascular disease Diseases 0.000 claims 4
• 210000003679 cervix uteri Anatomy 0.000 claims 4
• 201000010415 childhood type dermatomyositis Diseases 0.000 claims 4
• 230000007870 cholestasis Effects 0.000 claims 4
• 231100000359 cholestasis Toxicity 0.000 claims 4
• 208000020832 chronic kidney disease Diseases 0.000 claims 4
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 4
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 4
• 206010009887 colitis Diseases 0.000 claims 4
• 208000018631 connective tissue disease Diseases 0.000 claims 4
• 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 4
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 4
• 229940127089 cytotoxic agent Drugs 0.000 claims 4
• 230000006378 damage Effects 0.000 claims 4
• 231100000895 deafness Toxicity 0.000 claims 4
• 230000037336 dry skin Effects 0.000 claims 4
• 206010014599 encephalitis Diseases 0.000 claims 4
• 201000002491 encephalomyelitis Diseases 0.000 claims 4
• 201000010048 endomyocardial fibrosis Diseases 0.000 claims 4
• 231100000284 endotoxic Toxicity 0.000 claims 4
• 230000002346 endotoxic effect Effects 0.000 claims 4
• 208000010227 enterocolitis Diseases 0.000 claims 4
• 230000002327 eosinophilic effect Effects 0.000 claims 4
• 208000006881 esophagitis Diseases 0.000 claims 4
• 210000003238 esophagus Anatomy 0.000 claims 4
• 201000005884 exanthem Diseases 0.000 claims 4
• 239000002095 exotoxin Substances 0.000 claims 4
• 231100000776 exotoxin Toxicity 0.000 claims 4
• 210000001508 eye Anatomy 0.000 claims 4
• 208000030533 eye disease Diseases 0.000 claims 4
• 230000001815 facial effect Effects 0.000 claims 4
• 208000010706 fatty liver disease Diseases 0.000 claims 4
• 206010016629 fibroma Diseases 0.000 claims 4
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 4
• 210000000232 gallbladder Anatomy 0.000 claims 4
• 208000007565 gingivitis Diseases 0.000 claims 4
• 208000005017 glioblastoma Diseases 0.000 claims 4
• 201000010912 granulomatous dermatitis Diseases 0.000 claims 4
• 230000012010 growth Effects 0.000 claims 4
• 208000024963 hair loss Diseases 0.000 claims 4
• 210000003128 head Anatomy 0.000 claims 4
• 208000016354 hearing loss disease Diseases 0.000 claims 4
• 230000002440 hepatic effect Effects 0.000 claims 4
• 208000006454 hepatitis Diseases 0.000 claims 4
• 231100000283 hepatitis Toxicity 0.000 claims 4
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
• 230000000222 hyperoxic effect Effects 0.000 claims 4
• 230000002519 immonomodulatory effect Effects 0.000 claims 4
• 239000003018 immunosuppressive agent Substances 0.000 claims 4
• 229940125721 immunosuppressive agent Drugs 0.000 claims 4
• 208000021646 inflammation of heart layer Diseases 0.000 claims 4
• 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 4
• 208000014674 injury Diseases 0.000 claims 4
• 230000000968 intestinal effect Effects 0.000 claims 4
• 210000000936 intestine Anatomy 0.000 claims 4
• 230000001788 irregular Effects 0.000 claims 4
• 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
• 208000028867 ischemia Diseases 0.000 claims 4
• 201000010666 keratoconjunctivitis Diseases 0.000 claims 4
• 206010023365 keratopathy Diseases 0.000 claims 4
• 210000000867 larynx Anatomy 0.000 claims 4
• 201000010260 leiomyoma Diseases 0.000 claims 4
• 201000011486 lichen planus Diseases 0.000 claims 4
• 231100000515 lung injury Toxicity 0.000 claims 4
• 208000019420 lymphoid neoplasm Diseases 0.000 claims 4
• 208000008585 mastocytosis Diseases 0.000 claims 4
• 201000001441 melanoma Diseases 0.000 claims 4
• 239000012528 membrane Substances 0.000 claims 4
• 230000009245 menopause Effects 0.000 claims 4
• 208000030159 metabolic disease Diseases 0.000 claims 4
• 230000001394 metastastic effect Effects 0.000 claims 4
• 206010061289 metastatic neoplasm Diseases 0.000 claims 4
• 201000006417 multiple sclerosis Diseases 0.000 claims 4
• 201000000050 myeloid neoplasm Diseases 0.000 claims 4
• 210000003739 neck Anatomy 0.000 claims 4
• 210000005036 nerve Anatomy 0.000 claims 4
• 210000000653 nervous system Anatomy 0.000 claims 4
• 230000001537 neural effect Effects 0.000 claims 4
• 208000007538 neurilemmoma Diseases 0.000 claims 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims 4
• 230000001272 neurogenic effect Effects 0.000 claims 4
• 230000000926 neurological effect Effects 0.000 claims 4
• 230000004751 neurological system process Effects 0.000 claims 4
• 208000018360 neuromuscular disease Diseases 0.000 claims 4
• 239000003900 neurotrophic factor Substances 0.000 claims 4
• 235000020824 obesity Nutrition 0.000 claims 4
• 230000000414 obstructive effect Effects 0.000 claims 4
• 201000005737 orchitis Diseases 0.000 claims 4
• 201000008482 osteoarthritis Diseases 0.000 claims 4
• 201000004535 ovarian dysfunction Diseases 0.000 claims 4
• 231100000539 ovarian failure Toxicity 0.000 claims 4
• 210000001672 ovary Anatomy 0.000 claims 4
• 210000000496 pancreas Anatomy 0.000 claims 4
• 230000000737 periodic effect Effects 0.000 claims 4
• 201000001245 periodontitis Diseases 0.000 claims 4
• 206010034674 peritonitis Diseases 0.000 claims 4
• 208000017983 photosensitivity disease Diseases 0.000 claims 4
• 208000030761 polycystic kidney disease Diseases 0.000 claims 4
• 208000037244 polycythemia vera Diseases 0.000 claims 4
• 208000005987 polymyositis Diseases 0.000 claims 4
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 4
• 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 4
• 210000002307 prostate Anatomy 0.000 claims 4
• 208000020016 psychiatric disease Diseases 0.000 claims 4
• 230000001107 psychogenic effect Effects 0.000 claims 4
• 230000002685 pulmonary effect Effects 0.000 claims 4
• 206010037844 rash Diseases 0.000 claims 4
• 210000000664 rectum Anatomy 0.000 claims 4
• 201000009410 rhabdomyosarcoma Diseases 0.000 claims 4
• 201000000306 sarcoidosis Diseases 0.000 claims 4
• 230000037387 scars Effects 0.000 claims 4
• 208000010157 sclerosing cholangitis Diseases 0.000 claims 4
• 208000008742 seborrheic dermatitis Diseases 0.000 claims 4
• 230000009758 senescence Effects 0.000 claims 4
• 230000021317 sensory perception Effects 0.000 claims 4
• 206010040400 serum sickness Diseases 0.000 claims 4
• 201000009890 sinusitis Diseases 0.000 claims 4
• 231100000475 skin irritation Toxicity 0.000 claims 4
• 230000036556 skin irritation Effects 0.000 claims 4
• 231100000370 skin sensitisation Toxicity 0.000 claims 4
• 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
• 230000001148 spastic effect Effects 0.000 claims 4
• 230000007863 steatosis Effects 0.000 claims 4
• 231100000240 steatosis hepatitis Toxicity 0.000 claims 4
• 150000003431 steroids Chemical class 0.000 claims 4
• 210000002784 stomach Anatomy 0.000 claims 4
• 201000001297 telogen effluvium Diseases 0.000 claims 4
• 206010043207 temporal arteritis Diseases 0.000 claims 4
• 208000001608 teratocarcinoma Diseases 0.000 claims 4
• 210000001550 testis Anatomy 0.000 claims 4
• 230000002446 thrombocytic effect Effects 0.000 claims 4
• 210000001685 thyroid gland Anatomy 0.000 claims 4
• 208000021510 thyroid gland disease Diseases 0.000 claims 4
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 4
• 208000037816 tissue injury Diseases 0.000 claims 4
• 230000008733 trauma Effects 0.000 claims 4
• 230000009529 traumatic brain injury Effects 0.000 claims 4
• 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 4
• 208000025883 type III hypersensitivity disease Diseases 0.000 claims 4
• 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 4
• 208000009852 uremia Diseases 0.000 claims 4
• 210000003932 urinary bladder Anatomy 0.000 claims 4
• 210000004291 uterus Anatomy 0.000 claims 4
• 230000009385 viral infection Effects 0.000 claims 4
• 230000029663 wound healing Effects 0.000 claims 4
• 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims 3
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 3
• 208000024827 Alzheimer disease Diseases 0.000 claims 3
• 200000000007 Arterial disease Diseases 0.000 claims 3
• 206010003267 Arthritis reactive Diseases 0.000 claims 3
• 208000000104 Arthus reaction Diseases 0.000 claims 3
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 3
• 208000019872 Drug Eruptions Diseases 0.000 claims 3
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 3
• 206010070245 Foreign body Diseases 0.000 claims 3
• 208000022461 Glomerular disease Diseases 0.000 claims 3
• 208000006877 Insect Bites and Stings Diseases 0.000 claims 3
• 108010050904 Interferons Proteins 0.000 claims 3
• 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 3
• 206010024434 Lichen sclerosus Diseases 0.000 claims 3
• 206010049287 Lipodystrophy acquired Diseases 0.000 claims 3
• 208000005777 Lupus Nephritis Diseases 0.000 claims 3
• 208000016604 Lyme disease Diseases 0.000 claims 3
• 208000003250 Mixed connective tissue disease Diseases 0.000 claims 3
• 206010029164 Nephrotic syndrome Diseases 0.000 claims 3
• 208000022463 Pediatric systemic lupus erythematosus Diseases 0.000 claims 3
• 241000517324 Pediculidae Species 0.000 claims 3
• 206010037876 Rash papular Diseases 0.000 claims 3
• 208000033464 Reiter syndrome Diseases 0.000 claims 3
• 206010061481 Renal injury Diseases 0.000 claims 3
• 208000025747 Rheumatic disease Diseases 0.000 claims 3
• 208000027066 STING-associated vasculopathy with onset in infancy Diseases 0.000 claims 3
• 206010070834 Sensitisation Diseases 0.000 claims 3
• 206010054000 Type II hypersensitivity Diseases 0.000 claims 3
• 206010048222 Xerosis Diseases 0.000 claims 3
• 230000000172 allergic effect Effects 0.000 claims 3
• 208000019664 bone resorption disease Diseases 0.000 claims 3
• 208000000718 duodenal ulcer Diseases 0.000 claims 3
• 230000008482 dysregulation Effects 0.000 claims 3
• 206010014910 enthesopathy Diseases 0.000 claims 3
• 206010061989 glomerulosclerosis Diseases 0.000 claims 3
• 201000007162 hidradenitis suppurativa Diseases 0.000 claims 3
• 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 claims 3
• 230000000302 ischemic effect Effects 0.000 claims 3
• 230000000366 juvenile effect Effects 0.000 claims 3
• 208000037806 kidney injury Diseases 0.000 claims 3
• 208000006132 lipodystrophy Diseases 0.000 claims 3
• 201000006512 mast cell neoplasm Diseases 0.000 claims 3
• 208000010125 myocardial infarction Diseases 0.000 claims 3
• 208000004296 neuralgia Diseases 0.000 claims 3
• 208000021722 neuropathic pain Diseases 0.000 claims 3
• 208000012963 papular rash Diseases 0.000 claims 3
• 201000006292 polyarteritis nodosa Diseases 0.000 claims 3
• 201000001474 proteinuria Diseases 0.000 claims 3
• 230000010410 reperfusion Effects 0.000 claims 3
• 230000000552 rheumatic effect Effects 0.000 claims 3
• 230000008313 sensitization Effects 0.000 claims 3
• 208000020431 spinal cord injury Diseases 0.000 claims 3
• 230000008026 type II hypersensitivity Effects 0.000 claims 3
• 206010063409 Acarodermatitis Diseases 0.000 claims 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
• 201000001320 Atherosclerosis Diseases 0.000 claims 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
• 208000020084 Bone disease Diseases 0.000 claims 2
• 206010071443 Brachioradial pruritus Diseases 0.000 claims 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
• 208000008069 Geographic Atrophy Diseases 0.000 claims 2
• 201000005569 Gout Diseases 0.000 claims 2
• 206010061187 Haematopoietic neoplasm Diseases 0.000 claims 2
• 208000012659 Joint disease Diseases 0.000 claims 2
• 208000000112 Myalgia Diseases 0.000 claims 2
• 208000031888 Mycoses Diseases 0.000 claims 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
• 201000011152 Pemphigus Diseases 0.000 claims 2
• 241000721454 Pemphigus Species 0.000 claims 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
• 241000447727 Scabies Species 0.000 claims 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
• 230000003394 haemopoietic effect Effects 0.000 claims 2
• 201000005787 hematologic cancer Diseases 0.000 claims 2
• 208000002780 macular degeneration Diseases 0.000 claims 2
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
• 201000002266 mite infestation Diseases 0.000 claims 2
• 208000035824 paresthesia Diseases 0.000 claims 2
• 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
• 208000005687 scabies Diseases 0.000 claims 2
• 230000002568 urticarial effect Effects 0.000 claims 2
• WLNBMPZUVDTASE-HXIISURNSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical group [O-]S([O-])(=O)=O.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO WLNBMPZUVDTASE-HXIISURNSA-N 0.000 claims 1
• 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
• OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 claims 1
• 208000006386 Bone Resorption Diseases 0.000 claims 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
• 208000031229 Cardiomyopathies Diseases 0.000 claims 1
• 208000004575 Infectious Arthritis Diseases 0.000 claims 1
• 206010022971 Iron Deficiencies Diseases 0.000 claims 1
• 206010023421 Kidney fibrosis Diseases 0.000 claims 1
• 208000021908 Myocardial disease Diseases 0.000 claims 1
• 206010033645 Pancreatitis Diseases 0.000 claims 1
• 206010033647 Pancreatitis acute Diseases 0.000 claims 1
• 241000517307 Pediculus humanus Species 0.000 claims 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
• 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
• 101710097214 Protein N-terminal asparagine amidohydrolase Proteins 0.000 claims 1
• 102100034233 Protein N-terminal asparagine amidohydrolase Human genes 0.000 claims 1
• 208000034189 Sclerosis Diseases 0.000 claims 1
• XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims 1
• 241000272534 Struthio camelus Species 0.000 claims 1
• 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
• 206010042953 Systemic sclerosis Diseases 0.000 claims 1
• 206010060875 Uraemic pruritus Diseases 0.000 claims 1
• 201000003229 acute pancreatitis Diseases 0.000 claims 1
• 230000037446 allergic sensitization Effects 0.000 claims 1
• 230000024279 bone resorption Effects 0.000 claims 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 230000003831 deregulation Effects 0.000 claims 1
• 230000002183 duodenal effect Effects 0.000 claims 1
• 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
• 208000002557 hidradenitis Diseases 0.000 claims 1
• 210000003630 histaminocyte Anatomy 0.000 claims 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 1
• 230000002458 infectious effect Effects 0.000 claims 1
• 208000001024 intrahepatic cholestasis Diseases 0.000 claims 1
• 230000007872 intrahepatic cholestasis Effects 0.000 claims 1
• RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 claims 1
• 210000004877 mucosa Anatomy 0.000 claims 1
• 201000008383 nephritis Diseases 0.000 claims 1
• 150000003233 pyrroles Chemical class 0.000 claims 1
• 201000001223 septic arthritis Diseases 0.000 claims 1
• 210000000278 spinal cord Anatomy 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 50
• 238000011282 treatment Methods 0.000 abstract description 11
• 230000000694 effects Effects 0.000 abstract description 8
• 108091000080 Phosphotransferase Proteins 0.000 abstract description 6
• 102000020233 phosphotransferase Human genes 0.000 abstract description 6
• 241001465754 Metazoa Species 0.000 abstract description 4
• 230000002401 inhibitory effect Effects 0.000 abstract description 4
• RDRCCJPEJDWSRJ-UHFFFAOYSA-N pyridine;1h-pyrrole Chemical class C=1C=CNC=1.C1=CC=NC=C1 RDRCCJPEJDWSRJ-UHFFFAOYSA-N 0.000 abstract description 2
• 238000010348 incorporation Methods 0.000 description 47
• 239000011575 calcium Substances 0.000 description 29
• 238000009472 formulation Methods 0.000 description 20
• 229940002612 prodrug Drugs 0.000 description 18
• 239000000651 prodrug Substances 0.000 description 18
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 16
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 14
• 229910052805 deuterium Inorganic materials 0.000 description 14
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 14
• 125000004429 atom Chemical group 0.000 description 13
• 150000001721 carbon Chemical group 0.000 description 12
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 239000004480 active ingredient Substances 0.000 description 10
• 239000002585 base Substances 0.000 description 9
• 239000001257 hydrogen Substances 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
• 125000003342 alkenyl group Chemical group 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 239000004615 ingredient Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 229910052760 oxygen Inorganic materials 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
• 230000000155 isotopic effect Effects 0.000 description 7
• 150000003254 radicals Chemical class 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 108020003175 receptors Proteins 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
• 108010024121 Janus Kinases Proteins 0.000 description 6
• 102000015617 Janus Kinases Human genes 0.000 description 6
• 229920002472 Starch Polymers 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• 239000003513 alkali Substances 0.000 description 6
• 125000000304 alkynyl group Chemical group 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• 150000007524 organic acids Chemical class 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 5
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
• 150000001204 N-oxides Chemical class 0.000 description 5
• 102000001708 Protein Isoforms Human genes 0.000 description 5
• 108010029485 Protein Isoforms Proteins 0.000 description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 5
• 150000001450 anions Chemical class 0.000 description 5
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 238000004587 chromatography analysis Methods 0.000 description 5
• 125000004404 heteroalkyl group Chemical group 0.000 description 5
• 238000004949 mass spectrometry Methods 0.000 description 5
• 150000007522 mineralic acids Chemical class 0.000 description 5
• 239000008107 starch Substances 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• 239000011593 sulfur Substances 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
• 238000005481 NMR spectroscopy Methods 0.000 description 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
• 101710140204 Signal transducer and transcription activator Proteins 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 125000002252 acyl group Chemical group 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 239000000460 chlorine Substances 0.000 description 4
• 229910052801 chlorine Inorganic materials 0.000 description 4
• 239000010949 copper Substances 0.000 description 4
• 108010057085 cytokine receptors Proteins 0.000 description 4
• 102000003675 cytokine receptors Human genes 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 125000001188 haloalkyl group Chemical group 0.000 description 4
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
• 125000002950 monocyclic group Chemical group 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 238000000926 separation method Methods 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 description 4
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
• 239000004215 Carbon black (E152) Substances 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• 241001393742 Simian endogenous retrovirus Species 0.000 description 3
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 125000003282 alkyl amino group Chemical group 0.000 description 3
• 125000004414 alkyl thio group Chemical group 0.000 description 3
• 125000002947 alkylene group Chemical group 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 125000005605 benzo group Chemical group 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 125000001589 carboacyl group Chemical group 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 230000006806 disease prevention Effects 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
• YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 125000001624 naphthyl group Chemical group 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000005985 organic acids Nutrition 0.000 description 3
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
• 125000006684 polyhaloalkyl group Polymers 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• VSRSQDMWBSKNSF-UHFFFAOYSA-N propan-2-yl pyridine-3-carboxylate Chemical compound CC(C)OC(=O)C1=CC=CN=C1 VSRSQDMWBSKNSF-UHFFFAOYSA-N 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 125000004076 pyridyl group Chemical group 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 230000000707 stereoselective effect Effects 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 229910052722 tritium Inorganic materials 0.000 description 3
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 238000005750 Corey-Bakshi-Shibata reduction reaction Methods 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 239000005977 Ethylene Substances 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 102000042838 JAK family Human genes 0.000 description 2
• 108091082332 JAK family Proteins 0.000 description 2
• 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
• JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108050007918 Transcription factor STAT Proteins 0.000 description 2
• 102000000887 Transcription factor STAT Human genes 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 125000004442 acylamino group Chemical group 0.000 description 2
• ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
• 150000003973 alkyl amines Chemical class 0.000 description 2
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
• 125000004419 alkynylene group Chemical group 0.000 description 2
• 125000003435 aroyl group Chemical group 0.000 description 2
• 125000003710 aryl alkyl group Chemical group 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 150000001649 bromium compounds Chemical class 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 235000001465 calcium Nutrition 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• HJWLJNBZVZDLAQ-HAQNSBGRSA-N chembl2103874 Chemical compound C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-HAQNSBGRSA-N 0.000 description 2
• 150000001805 chlorine compounds Chemical class 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 235000009508 confectionery Nutrition 0.000 description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000001952 enzyme assay Methods 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• 238000001640 fractional crystallisation Methods 0.000 description 2
• 125000002541 furyl group Chemical group 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 125000004438 haloalkoxy group Chemical group 0.000 description 2
• 150000002431 hydrogen Chemical class 0.000 description 2
• 230000003301 hydrolyzing effect Effects 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 150000002466 imines Chemical class 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 150000004694 iodide salts Chemical class 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 125000001181 organosilyl group Chemical class [SiH3]* 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 229950010765 pivalate Drugs 0.000 description 2
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 238000012877 positron emission topography Methods 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• 229960004919 procaine Drugs 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• AHIHJODVQGBOND-UHFFFAOYSA-N propan-2-yl hydrogen carbonate Chemical compound CC(C)OC(O)=O AHIHJODVQGBOND-UHFFFAOYSA-N 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• CLAOCVVWIKGTOP-UHFFFAOYSA-N propyl pyridine-3-carboxylate Chemical compound CCCOC(=O)C1=CC=CN=C1 CLAOCVVWIKGTOP-UHFFFAOYSA-N 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 150000003512 tertiary amines Chemical class 0.000 description 2
• YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
• IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
• POPHMOPNVVKGRW-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7-octahydronaphthalene Chemical compound C1CCC2CCCCC2=C1 POPHMOPNVVKGRW-UHFFFAOYSA-N 0.000 description 1
• 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• UCRIXEWTILHNCG-UHFFFAOYSA-N 1-ethyl-2h-pyridine Chemical compound CCN1CC=CC=C1 UCRIXEWTILHNCG-UHFFFAOYSA-N 0.000 description 1
• SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
• PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
• RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 1
• HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 241000723346 Cinnamomum camphora Species 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical group NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
• HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 125000005631 S-sulfonamido group Chemical group 0.000 description 1
• 102000014400 SH2 domains Human genes 0.000 description 1
• 108050003452 SH2 domains Proteins 0.000 description 1
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
• 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
• 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
• 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
• 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
• 125000004450 alkenylene group Chemical group 0.000 description 1
• 125000005055 alkyl alkoxy group Chemical group 0.000 description 1
• 125000001118 alkylidene group Chemical group 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 125000005018 aryl alkenyl group Chemical group 0.000 description 1
• 150000003975 aryl alkyl amines Chemical class 0.000 description 1
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
• 125000005015 aryl alkynyl group Chemical group 0.000 description 1
• 125000001769 aryl amino group Chemical group 0.000 description 1
• 125000005110 aryl thio group Chemical group 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 229910052792 caesium Inorganic materials 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 229960000846 camphor Drugs 0.000 description 1
• 229930008380 camphor Natural products 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000001734 carboxylic acid salts Chemical class 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• YBXCVZOGEOAXNA-UHFFFAOYSA-N cyclopropyl pyridine-3-carboxylate Chemical compound O=C(OC1CC1)C1=CC=CN=C1 YBXCVZOGEOAXNA-UHFFFAOYSA-N 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 108091007930 cytoplasmic receptors Proteins 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
• 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 125000006001 difluoroethyl group Chemical group 0.000 description 1
• LTVOKYUPTHZZQH-UHFFFAOYSA-N difluoromethane Chemical group F[C]F LTVOKYUPTHZZQH-UHFFFAOYSA-N 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 125000004982 dihaloalkyl group Chemical group 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
• 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 230000002692 disease related effect Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000009513 drug distribution Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
• KNFXXAGQEUUZAZ-UHFFFAOYSA-N ethyl ethaneperoxoate Chemical compound CCOOC(C)=O KNFXXAGQEUUZAZ-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 229940114119 gentisate Drugs 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 125000000262 haloalkenyl group Chemical group 0.000 description 1
• 125000004995 haloalkylthio group Chemical group 0.000 description 1
• 125000005347 halocycloalkyl group Chemical group 0.000 description 1
• 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000009413 insulation Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 229950000886 isetionate Drugs 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 description 1
• JHPGNPYRXIEHLD-UHFFFAOYSA-N methoxymethyl pyridine-3-carboxylate Chemical compound COCOC(=O)C1=CC=CN=C1 JHPGNPYRXIEHLD-UHFFFAOYSA-N 0.000 description 1
• CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 1
• 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
• 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
• 125000006682 monohaloalkyl group Chemical group 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• UQEIFYRRSNJVDO-UHFFFAOYSA-N n,n-dibenzyl-2-phenylethanamine Chemical compound C=1C=CC=CC=1CN(CC=1C=CC=CC=1)CCC1=CC=CC=C1 UQEIFYRRSNJVDO-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
• FBUKVWPVBMHYJY-UHFFFAOYSA-N noncarboxylic acid Natural products CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 229940039748 oxalate Drugs 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
• 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
• 125000005561 phenanthryl group Chemical group 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 230000009822 protein phosphorylation Effects 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 238000012797 qualification Methods 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 238000010956 selective crystallization Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000005556 structure-activity relationship Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 229940086735 succinate Drugs 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
• QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
• 229960004559 theobromine Drugs 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000004149 thio group Chemical group *S* 0.000 description 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 239000003860 topical agent Substances 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 238000012384 transportation and delivery Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
• 229940066528 trichloroacetate Drugs 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• 125000005423 trihalomethanesulfonamido group Chemical group 0.000 description 1
• 125000005152 trihalomethanesulfonyl group Chemical group 0.000 description 1
• 125000004951 trihalomethoxy group Chemical group 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 102000042286 type I cytokine receptor family Human genes 0.000 description 1
• 108091052247 type I cytokine receptor family Proteins 0.000 description 1
• 102000042287 type II cytokine receptor family Human genes 0.000 description 1
• 108091052254 type II cytokine receptor family Proteins 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 239000006200 vaporizer Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1